ThermoGenesis Corp.? has received approval from India?s Ministry of Health to begin commercial sales of its proprietary product that processes stem cells from cord blood.
The Rancho Cordova-based company will be working closely with product distributor Fenwal Inc. to sell the AutoXpress System (AXP) in India.
Approval in India comes as the company awaits approval for sales in China, expected early this year.
?The AXP represents advanced stem cell technology and India is one of the largest and fastest growing markets in the world,? Vikram Karnani, Fenwal vice president for therapeutics, said in a news release.
ThermoGenesis (Nasdaq: KOOL) stock closed at 84 cents Friday. It was trading at 90 cents by midday Monday. The 52-week high was $3.75 in January 2011; the low, 70 cents Jan. 3, 2012.
Click here for the full press release.
ThermoGenesis Corp.? has received approval from India?s Ministry of Health to begin commercial sales of its proprietary product that processes stem cells from cord blood.
The Rancho Cordova-based company will be working closely with product distributor Fenwal Inc. to sell the AutoXpress System (AXP) in India.
Approval in India comes as the company awaits approval for sales in China, expected early this year.
?The AXP represents advanced stem cell technology and India is one of the largest and fastest growing markets in the world,? Vikram Karnani, Fenwal vice president for therapeutics, said in a news release.
ThermoGenesis (Nasdaq: KOOL) stock closed at 84 cents Friday. It was trading at 90 cents by midday Monday. The 52-week high was $3.75 in January 2011; the low, 70 cents Jan. 3, 2012.
Click here for the full press release.
slim dunkin slim dunkin will rogers ohio university ohio university etta james keystone xl pipeline
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.